{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:27:15Z","timestamp":1763684835290,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101005142"],"award-info":[{"award-number":["101005142"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejps.2023.106418","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:44:19Z","timestamp":1677757459000},"page":"106418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-7760","authenticated-orcid":false,"given":"Nadia","family":"Baalbaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Duijvelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medhat M.","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job","family":"Schippers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre M.","family":"Bet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Twisk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Fritchley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazien","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke H.","family":"Maitland-van der Zee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm Jan","family":"Bogaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurjan","family":"Aman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imke H.","family":"Bartelink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejps.2023.106418_bib0046","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365515709101220","article-title":"A study of serum Glycoproteins in Cancer","volume":"9","author":"Almquist","year":"1957","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"9","key":"10.1016\/j.ejps.2023.106418_bib0011","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respiratory Med."},{"issue":"23","key":"10.1016\/j.ejps.2023.106418_bib0007","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1161\/CIRCULATIONAHA.112.134304","article-title":"Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib","volume":"126","author":"Aman","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ejps.2023.106418_bib0020","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.leukres.2010.07.014","article-title":"Relationship of serum imatinib trough level and response in CML patients: long term follow-up","volume":"34","author":"Awidi","year":"2010","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.ejps.2023.106418_bib0025","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/psp4.12718","article-title":"Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: lessons from the CounterCOVID - imatinib study","volume":"10","author":"Bartelink","year":"2021","journal-title":"CPT Pharmacom & Syst Pharma"},{"issue":"3","key":"10.1016\/j.ejps.2023.106418_bib0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejps.2023.106418_bib0029","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2023.106418_bib0049","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03006-2020","article-title":"Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome","volume":"56","author":"Chen","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.ejps.2023.106418_bib0010","doi-asserted-by":"crossref","first-page":"e85231","DOI":"10.1371\/journal.pone.0085231","article-title":"Abl Family Kinases Regulate Endothelial Barrier Function In Vitro and in Mice. Vinci MC, editor","volume":"8","author":"Chislock","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejps.2023.106418_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/thoraxjnl-2021-217080","article-title":"Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort","volume":"77","author":"Clift","year":"2022","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.ejps.2023.106418_bib0016","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.ejps.2023.106418_bib0038","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.ejps.2023.106418_bib0017","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable\/Metastatic Gastrointestinal Stromal Tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"JCO."},{"year":"2021","series-title":"Acute Respiratory Distress Syndrome","author":"Diamond","key":"10.1016\/j.ejps.2023.106418_bib0002"},{"issue":"4","key":"10.1016\/j.ejps.2023.106418_bib0012","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2213-2600(22)00052-2","article-title":"Long-term clinical outcomes of COVID-19 patients treated with imatinib","volume":"10","author":"Duijvelaar","year":"2022","journal-title":"Lancet Respiratory Med."},{"issue":"6","key":"10.1016\/j.ejps.2023.106418_bib0055","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/FJC.0000000000001344","article-title":"Cardiac Safety of Imatinib for the Treatment of COVID-19: a Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"80","author":"Duijvelaar","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2023.106418_bib0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40262-016-0439-7","article-title":"Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients","volume":"56","author":"Farag","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2023.106418_bib0042","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0167-4838(00)00153-9","article-title":"Alpha-1-acid glycoprotein","volume":"1482","author":"Fournier","year":"2000","journal-title":"Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology"},{"issue":"7\u20138","key":"10.1016\/j.ejps.2023.106418_bib0040","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.drudis.2008.12.011","article-title":"Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations","volume":"14","author":"Gabrielsson","year":"2009","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.ejps.2023.106418_bib0052","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00280-012-2035-3","article-title":"Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?","volume":"71","author":"Gandia","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106418_bib0001","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5694\/mja2.50674","article-title":"COVID -19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre- COVID -19 ARDS","volume":"213","author":"Gibson","year":"2020","journal-title":"Med. J. Aust."},{"issue":"4","key":"10.1016\/j.ejps.2023.106418_bib0047","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","article-title":"CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity","volume":"66","author":"Gr\u00e9en","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"22","key":"10.1016\/j.ejps.2023.106418_bib0028","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/j.ejps.2023.106418_bib0043","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1359-6101(02)00054-0","article-title":"\u03b11-Acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties","volume":"14","author":"Hochepied","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.ejps.2023.106418_bib0050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1365-2125.2012.04422.x","article-title":"Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours: population pharmacokinetics of total and free imatinib","volume":"75","author":"Haouala","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2023.106418_bib0033","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ejps.2023.106418_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.02-0195fje","article-title":"Down-regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved","volume":"16","author":"Jover","year":"2002","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.ejps.2023.106418_bib0024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","article-title":"Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group","volume":"55","author":"Judson","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2023.106418_bib0019","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cncr.24928","article-title":"Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejps.2023.106418_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)00015-8","article-title":"Drug binding to human alpha-1-acid glycoprotein in health and disease","volume":"40","author":"Kremer","year":"1988","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.ejps.2023.106418_bib0015","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejps.2023.106418_bib0021","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00228-009-0779-4","article-title":"Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example","volume":"66","author":"Li-Wan-Po","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2023.106418_bib0030","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejps.2023.106418_bib0053","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","article-title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","volume":"63","author":"Menon-Andersen","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejps.2023.106418_bib0005","doi-asserted-by":"crossref","first-page":"967","DOI":"10.5005\/jp-journals-10071-23547","article-title":"Mechanisms of Hypoxia in COVID-19 Patients: a Pathophysiologic Reflection","volume":"24","author":"Nitsure","year":"2020","journal-title":"Indian J Crit Care Med"},{"issue":"9","key":"10.1016\/j.ejps.2023.106418_bib0009","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"Peng","year":"2005","journal-title":"Clinical Pharmacokinetics of Imatinib: Clinical Pharmacokinetics"},{"issue":"8","key":"10.1016\/j.ejps.2023.106418_bib0018","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejps.2023.106418_bib0032","doi-asserted-by":"crossref","first-page":"21519","DOI":"10.1038\/s41598-021-00927-x","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection","volume":"11","author":"Prozan","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ejps.2023.106418_bib0008","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/ATVBAHA.115.305085","article-title":"Targeting Abl Kinases to Regulate Vascular Leak During Sepsis and Acute Respiratory Distress Syndrome","volume":"35","author":"Rizzo","year":"2015","journal-title":"ATVB"},{"key":"10.1016\/j.ejps.2023.106418_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.686251","article-title":"Into the Labyrinth of the Lipocalin \u03b11-Acid Glycoprotein","volume":"12","author":"Ruiz","year":"2021","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.ejps.2023.106418_bib0023","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","article-title":"Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study","volume":"60","author":"Schmidli","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2023.106418_bib0044","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2023.106418_bib0022","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders","volume":"65","author":"Singh","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2023.106418_bib0004","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10456-021-09805-6","article-title":"COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects","volume":"24","author":"Smadja","year":"2021","journal-title":"Angiogenesis"},{"issue":"12","key":"10.1016\/j.ejps.2023.106418_bib0039","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.ejps.2023.106418_bib0051","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.11-1396","article-title":"Introduction to drug pharmacokinetics in the critically ill patient","volume":"141","author":"Smith","year":"2012","journal-title":"Chest"},{"issue":"5\u20136","key":"10.1016\/j.ejps.2023.106418_bib0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000324900","article-title":"Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase","volume":"87","author":"Takahashi","year":"2011","journal-title":"Pharmacology"},{"issue":"6","key":"10.1016\/j.ejps.2023.106418_bib0036","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia","volume":"88","author":"Takahashi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2023.106418_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","article-title":"COVID-19: the vasculature unleashed","volume":"20","author":"Teuwen","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.ejps.2023.106418_bib0006","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMra1608077","article-title":"Acute Respiratory Distress Syndrome. Drazen JM, editor","volume":"377","author":"Thompson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ejps.2023.106418_bib0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2023.106418_bib0054","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejps.2023.106418_bib0037","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.bjc.6605584","article-title":"Imatinib plasma levels: correlation with clinical benefit in GIST patients","volume":"102","author":"Widmer","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.ejps.2023.106418_bib0026","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability","volume":"98","author":"Widmer","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"7821","key":"10.1016\/j.ejps.2023.106418_bib0034","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:06:55Z","timestamp":1760530015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":55,"alternative-id":["S0928098723000490"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106418","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106418"}}